Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

Zacks Investment Research News Agency

Yesterday•Zacks Investment Research

Stocks Medium Importance Neutral

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.

Related Symbols 1

M MRNA MRNA

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #3,214

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones

Comments

User Menu